163 related articles for article (PubMed ID: 9074718)
21. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
[TBL] [Abstract][Full Text] [Related]
22. Familial essential thrombocythemia with spontaneous megakaryocyte colony formation and acquired JAK2 mutations.
Higgs JR; Sadek I; Neumann PE; Ing VW; Renault NK; Berman JN; Greer WL
Leukemia; 2008 Aug; 22(8):1551-6. PubMed ID: 18496561
[TBL] [Abstract][Full Text] [Related]
23. [The chronic Philadelphia chromosome-negative myeloproliferative syndrome I. Pathogenesis and pathophysiology].
Hasselbalch HC; Mourits-Andersen HT; Jensen BA; Jensen MK; Nielsen OJ
Ugeskr Laeger; 2001 Apr; 163(18):2471-3. PubMed ID: 11379259
[TBL] [Abstract][Full Text] [Related]
24. Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin-3.
Kobayashi S; Teramura M; Hoshino S; Motoji T; Oshimi K; Mizoguchi H
Br J Haematol; 1993 Apr; 83(4):539-44. PubMed ID: 7686030
[TBL] [Abstract][Full Text] [Related]
25. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
[TBL] [Abstract][Full Text] [Related]
26. Aberrant proplatelet formation in chronic myeloproliferative neoplasms.
Muth M; Büsche G; Bock O; Hussein K; Kreipe H
Leuk Res; 2010 Nov; 34(11):1424-9. PubMed ID: 20430444
[TBL] [Abstract][Full Text] [Related]
27. Etiology of the myeloproliferative disorders: the role of thrombopoietin.
Kaushansky K
Semin Hematol; 2003 Jan; 40(1 Suppl 1):6-9. PubMed ID: 12682875
[TBL] [Abstract][Full Text] [Related]
28. [Dysmegakaryocytopoiesis and thrombopoiesis in autoimmune thrombocytopenias].
Bellucci S
C R Seances Soc Biol Fil; 1996; 190(5-6):541-8. PubMed ID: 9074719
[TBL] [Abstract][Full Text] [Related]
29. Spontaneous megakaryocytic colony formation does not discriminate between essential thrombocythemia and polycythemia vera.
Escoffre-Barbe M; Amiot L; Beaucournu P; Jego P; Grulois I; Grosbois B; Bernard M; Fest T; Lamy T; Fardel O
Am J Hematol; 2006 Jul; 81(7):554-6. PubMed ID: 16755572
[TBL] [Abstract][Full Text] [Related]
30. Spontaneous proliferative megakaryocytopoiesis and platelet hyperreactivity in essential thrombocythemia: is thrombopoietin the link?
Bellucci S; Michiels JJ
Ann Hematol; 2000 Feb; 79(2):51-8. PubMed ID: 10741915
[TBL] [Abstract][Full Text] [Related]
31. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
32. Megakaryocytopoiesis in vitro: from the stem cells' perspective.
Cardier JE; Foster DC; Lok S; Jacobsen SE; Murphy MJ
Stem Cells; 1996; 14 Suppl 1():163-72. PubMed ID: 11012217
[TBL] [Abstract][Full Text] [Related]
33. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
34. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
35. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
36. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
Bock O
Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
[TBL] [Abstract][Full Text] [Related]
37. Myelofibrosis: experimental models and human studies.
Taskin AL; Cohen-Solal K; Le Couedic JP; Abina MA; Villeval JL; Debili N; Casadevall N; Vainchenker W; Wendling F
Stem Cells; 1998; 16 Suppl 2():155-64. PubMed ID: 11012187
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
[TBL] [Abstract][Full Text] [Related]
39. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders.
Martyré MC
Leuk Lymphoma; 1995 Dec; 20(1-2):39-44. PubMed ID: 8750621
[TBL] [Abstract][Full Text] [Related]
40. In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes.
Balduini A; Badalucco S; Pugliano MT; Baev D; De Silvestri A; Cattaneo M; Rosti V; Barosi G
PLoS One; 2011; 6(6):e21015. PubMed ID: 21698292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
